Resolution of inflammation as a novel chemopreventive strategy

Seminars in Immunopathology

Volumn 35, Issue 2, 2013, Pages 151-161

  Lee, Ha Na ^a   Na, Hye Kyung ^b   Surh, Young Joon ^a,c  

^a Seoul National University   (South Korea)

^b Sungshin Women's University   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Cancer; Chemoprevention; Inflammation associated carcinogenesis; Lipid mediator class switching; Lipid mediators; Prostaglandins; Resolution of inflammation; Resolvins

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; ARACHIDONATE 15 LIPOXYGENASE; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOTRIENE; LIPID; LIPOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; PROSTAGLANDIN D SYNTHASE; RESOLVIN; THROMBOXANE SYNTHASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CHEMOPROPHYLAXIS; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; DNA DAMAGE; EPIGENETICS; GENE EXPRESSION REGULATION; GENOMIC INSTABILITY; HUMAN; IMMUNOSTIMULATION; INFLAMMATION; INTRACELLULAR SIGNALING; MOLECULAR MODEL; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; DOCOSAHEXAENOIC ACIDS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPOXINS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84874107358     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-013-0363-y     Document Type: Review

References (69)

1. Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454:428-435
2. Philip M, Rowley DA, Schreiber H (2004) Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 14:433-439
3. Vendramini-Costa DB, Carvalho JE (2012) Molecular link mechanisms between inflammation and cancer. Curr Pharm Des 18:3831-3852
4. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436-444
5. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860-867
6. Radisky DC, Kenny PA, Bissell MJ (2007) Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT? J Cell Biochem 101:830-839
7. Colville-Nash PR, Gilroy DW (2001) Potential adverse effects of cyclooxygenase-2 inhibition: evidence from animal models of inflammation. BioDrugs 15:1-9
8. Stevens DL (1995) Could nonsteroidal antiinflammatory drugs (NSAIDs) enhance the progression of bacterial-infections to toxic shock syndrome. Clin Infect Dis 21:977-980
9. Rodriguez-Vita J, Lawrence T (2010) The resolution of inflammation and cancer. Cytokine Growth Factor Rev 21:61-65
10. Wilting J, Becker J, Buttler K, Weich HA (2009) Lymphatics and inflammation. Curr Med Chem 16:4581-4592
11. Huynh MLN, Fadok VA, Henson PM (2002) Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta 1 secretion and the resolution of inflammation. J Clin Invest 109:41-50
12. Opal SM, DePalo VA (2000) Anti-inflammatory cytokines. Chest 117:1162-1172
13. Samuelsson B (1983) From studies of biochemical-mechanism to novel biological mediators - prostaglandin endoperoxides, thromboxanes, and leukotrienes. Angew Chem Int Edit 22:805-815
14. Ricciotti E, FitzGerald GA (2011) Prostaglandins and inflammation. Arterioscler Thromb Vasc 31:986-1000
15. 2 signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors. Gastroenterology 140:596-607.e7
16. Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, Pandher K, Lapointe JM, Saha S, Roach ML, Carter D, Thomas NA, Durtschi BA, McNeish JD, Hambor JE, Jakobsson PJ, Carty TJ, Perez JR, Audoly LP (2003) Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci U S A 100:9044-9049
17. 2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest 110:651-658
18. 4 hydrolase-deficient mice. J Immunol 163:6810-6819
19. Serhan CN, Savill J (2005) Resolution of inflammation: the beginning programs the end. Nat Immunol 6:1191-1197
20. Lawrence T, Willoughby DA, Gilroy DW (2002) Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2:787-795
21. Il Lee S, Zuo XS, Shureiqi I (2011) 15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in? Cancer Metastasis Rev 30:481-491
22. Serhan CN, Petasis NA (2011) Resolvins and protectins in inflammation resolution. Chem Rev 111:5922-5943
23. Schwab JM, Chiang N, Arita M, Serhan CN (2007) Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447:869-874
24. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, Blumberg RS, Serhan CN (2005) Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A 102:7671-7676
25. Hasturk H, Kantarci A, Ohira T, Arita M, Ebrahimi N, Chiang N, Petasis NA, Levy BD, Serhan CN, Van Dyke TE (2006) RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis. FASEB J 20:401-403
26. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN (2001) Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2:612-619
27. Spite M, Serhan CN (2010) Novel lipid mediators promote resolution of acute inflammation impact of aspirin and statins. Circ Res 107:1170-1184
28. 2 inhibits airway dendritic cell migration and function in steady state conditions by selective activation of the D prostanoid receptor 1. J Immunol 171:3936-3940
29. 2 metabolite generated during inflammatory processes. J Biol Chem 277:10459-10466
30. 2, an electrophilic lipid mediator of anti-inflammatory and pro-resolving signaling. Biochem Pharmacol 82:1335-1351
31. Lee YC (2004) The role of PTEN in allergic inflammation. Arch Immunol Ther Exp 52:250-254
32. Croker BA, Kiu H, Pellegrini M, Toe J, Preston S, Metcalf D, O'Donnell JA, Cengia LH, McArthur K, Nicola NA, Alexander WS, Roberts AW (2012) IL-6 promotes acute and chronic inflammatory disease in the absence of SOCS3. Immunol Cell Biol 90:124-129
33. Lawrence T, Bebien M, Liu GY, Nizet V, Karin M (2005) IKK alpha limits macrophage NF-kappa B activation and contributes to the resolution of inflammation. Nature 434:1138-1143
34. Balode L, Strazda G, Jurka N, Kopeika U, Kislina A, Bukovskis M, Beinare M, Gardjusina V, Taivans I (2012) Lipoxygenase-derived arachidonic acid metabolites in chronic obstructive pulmonary disease. Medicina (Kaunas) 48:292-298
35. Wu WKK, Sung JJY, Lee CW, Yu J, Cho CH (2010) Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Lett 295:7-16
36. 2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30:377-386
37. s-axin-beta-catenin signaling axis. Science 310:1504-1510
38. 2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276:18075-18081
39. 2 is mediated by hypoxia-inducible factor 1. Cancer Res 63:2330-2334
40. 2. FEBS Lett 580:3368-3374
41. 2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 59:4574-4577
42. 2 synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res 62:63-66
43. Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Lonnroth C, Lundholm K (2007) Prostanoid receptor expression in colorectal cancer related to tumor stage, differentiation and progression. Acta Oncol 46:1107-1112
44. Cutler NS, Graves-Deal R, LaFleur BJ, Gao ZQ, Boman BM, Whitehead RH, Terry E, Morrow JD, Coffey RJ (2003) Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells. Cancer Res 63:1748-1751
45. 4 in colon carcinogenesis. Cancer Res 62:28-32
46. 2α stimulates motility and invasion in colorectal tumor cells. Int J Cancer 121:734-740
47. Goldblatt D, Thrasher AJ (2000) Chronic granulomatous disease. Clin Exp Immunol 122:1-9
48. Morimoto K, Janssen WJ, Terada M (2012) Defective efferocytosis by alveolar macrophages in IPF patients. Respir Med 106:1800-1803
49. Imanishi T, Akasaka T (2013) Novel strategies to target inflammatory processes in atherosclerosis. Curr Pharm Des (in press)
50. Herlong JL, Scott TR (2006) Positioning prostanoids of the D and J series in the immunopathogenic scheme. Immunol Lett 102:121-131
51. 2 synthase expression in human lung tumors. Lung Cancer 70:103-109
52. 2 synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma. Mol Cancer Ther 7:3420-3428
53. Eichele K, Ramer R, Hinz B (2008) Decisive role of cyclooxygenase-2 and lipocalin-type prostaglandin D synthase in chemotherapeutics-induced apoptosis of human cervical carcinoma cells. Oncogene 27:3032-3044
54. 2 is a mast cell-derived antiangiogenic factor in lung carcinoma. Proc Natl Acad Sci U S A 108:19802-19807
55. Min/+ mice. Cancer Res 67:881-889
56. Janakiram NB, Rao CV (2009) Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer. Curr Mol Med 9:565-579
57. Shureiqi I, Wojno KJ, Poore JA, Reddy RG, Moussali MJ, Spindler SA, Greenson JK, Normolle D, Hasan AA, Lawrence TS, Brenner DE (1999) Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis 20:1985-1995
58. Kamitani H, Geller M, Eling T (1998) Expression of 15-lipoxygenase by human colorectal carcinoma Caco-2 cells during apoptosis and cell differentiation. J Biol Chem 273:21569-21577
59. Kim JS, Baek SJ, Bottone FG, Sali T, Eling TE (2005) Overexpression of 15-lipoxygenase-1 induces growth arrest through phosphorylation of p53 in human colorectal cancer cells. Mol Cancer Res 3:511-517
60. Yuri M, Sasahira T, Nakai K, Ishimaru S, Ohmori H, Kuniyasu H (2007) Reversal of expression of 15-lipoxygenase-1 to cyclooxygenase-2 is associated with development of colonic cancer. Histopathology 51:520-527
61. Jiang WG, Douglas-Jones A, Mansel RE (2003) Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins Leukot Essent 69:275-281
62. 4 reduces lipopolysaccharide-induced inflammation in macrophages and intestinal epithelial cells through inhibition of nuclear factor-kappaB activation. J Pharmacol Exp Ther 332:541-548
63. 4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci U S A 99:13266-13271
64. 4 inhibit tumor necrosis factor 1 alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J Exp Med 189:1923-1929
65. 4 and its analog suppress hepatocellular carcinoma via remodeling tumor microenvironment. Cancer Lett 309:85-94
66. Ishida T, Yoshida M, Arita M, Nishitani Y, Nishiumi S, Masuda A, Mizuno S, Takagawa T, Morita Y, Kutsumi H, Inokuchi H, Serhan CN, Blumberg RS, Azuma T (2010) Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflamm Bowel Dis 16:87-95
67. Nowak J, Weylandt KH, Habbel P, Wang J, Dignass A, Glickman JN, Kang JX (2007) Colitis-associated colon tumorigenesis is suppressed in transgenic mice rich in endogenous n-3 fatty acids. Carcinogenesis 28:1991-1995
68. 2 induces IL-8 production in human T cells by a mitogen-activated protein kinase pathway. J Immunol 168:1372-1379
69. 2 regulates apoptosis induction and nuclear factor-kappa B activation via a peroxisome proliferator-activated receptor-gamma-independent mechanism in hepatocellular carcinoma. Lab Invest 83:1529-1539